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(aMCI), 13 vascular dementia (VaD), and 12 Parkinson’s 
disease (PD) patients with those of 112 matched controls 
by fluorescence two-dimensional differential gel electro-
phoresis in independent discovery and verification sets. The 
optimal sum score of four mass spectrometry (MS)-iden-
tified proteins yielded a sensitivity of 94 % and a specific-
ity of 89 % (AUC = 0.969, 95 % CI = 0.944–0.994) to 
differentiate AD patients from healthy controls. To bridge 
the gap between bench and bedside, we developed a high-
throughput multiplex protein biochip with great potential 
for routine AD screening. For convenience and speed of 
application, this array combines loading control-assisted 
protein quantification of monoamine oxidase B and tropo-
myosin 1 with protein-based genotyping for single nucleo-
tide polymorphisms (SNPs) in the apolipoprotein E and 
glutathione S-transferase omega 1 genes. Based on mini-
mally invasive blood drawing, this innovative protein bio-
chip enables identification of AD patients with an accuracy 
of 92 % in a single analytical step in less than 4 h.
Keywords Alzheimer’s disease · Diagnosis · Blood 
platelets · Biomarker · Multiplex protein biochip · 
Hematologic test
Introduction
Alzheimer’s disease (AD), a multifactorial neurodegenera-
tive disorder, represents the most frequent cause (ca. 60 %) 
of dementia [8], which has been predicted to impact the 
quality of life of more than 100 million people by 2050 [1]. 
Although numerous studies have tried to establish causal 
links between the pathogenesis of neurodegeneration and 
dietary, environmental, genetic, and age-related factors 
[22], the aetiology of AD remains ill-defined. As a result 
Abstract Alzheimer’s disease (AD), a multifactorial neu-
rodegenerative condition caused by genetic and environ-
mental factors, is diagnosed using neuropsychological tests 
and brain imaging; molecular diagnostics are not routinely 
applied. Studies have identified AD-specific cerebrospinal 
fluid (CSF) biomarkers but sample collection requires inva-
sive lumbar puncture. To identify AD-modulated proteins 
in easily accessible blood platelets, which share biochemi-
cal signatures with neurons, we compared platelet lysates 
from 62 AD, 24 amnestic mild cognitive impairment 
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of the heterogeneity of the disease, it has been subdivided 
into early-onset familial AD (EOFAD) and late-onset AD 
(LOAD). EOFAD is primarily due to genetic pathology 
with mutations evident in the genes encoding presenilin 1 
and 2 [54] and the amyloid precursor protein (APP) [8]. 
LOAD, however, is more prevalent (greater than 95 %), has 
an onset age of at least 65 years, and just one known major 
genetic risk factor, the ε4 allele of the APOE gene [27]. 
While genetic testing in combination with familial history 
helps diagnose EOFAD, valid ante mortem tests for LOAD 
have yet to be developed. Recently, claims emerged that 
there is an urgent need to develop objective diagnostic tools 
that incorporate easily available AD biomarkers [35, 49].
Classic neuropathological characteristics of AD are 
accumulations of beta-amyloid (Aβ) plaques and neurofi-
brillary tangles in cortical brain regions [8, 11]. Both fea-
tures are reflected in cerebrospinal fluid (CSF) since tangles 
arise as a consequence of increased levels of phospho-tau 
protein, whereas plaques sequester Aβ peptides and thus 
lower Aβ concentrations in CSF [29]. Consequently, most 
studies undertaken to characterize AD-specific biomarkers 
have focused on these events by analysing CSF. Neverthe-
less, since the cause of LOAD is multifactorial [36], it is 
improbable that single (protein) markers can accurately 
define this complex pathology; an algorithm based on mul-
tiple biomarkers should deliver a more accurate clinical 
diagnosis [35]. Indeed, when applied to AD, it was recog-
nized that a combination of CSF Aβ and (phospho-)tau plus 
newly discovered candidates offered superior diagnostic 
accuracy compared to single markers [17]. However, CSF 
sample collection by lumbar puncture is inconvenient for 
routine screening. As less invasive alternatives, brain imag-
ing of temporal lobe atrophy, glucose metabolism, or Aβ 
burden [37] are applied in specialized clinics. However, 
these methods are expensive and not readily accessible. 
Therefore, a simple diagnostic screening assay to rapidly 
and objectively detect AD parameters would be very use-
ful [35]. In particular, a blood test using a minimally inva-
sive sampling route and offering reliable diagnosis by an 
AD-specific biomarker profile would be a significant clini-
cal advancement, even if detailed clinical patient follow-up 
would still be required [31, 35]. Whole blood is an attrac-
tive sample material since it is a source of cellular and 
plasmatic proteins that can easily be extracted. Moreover, 
blood contains platelets, which have increasingly been 
utilized in the search for AD biomarkers [14, 68]. In fact, 
platelets are an acknowledged surrogate for neuron physi-
ology since they are the major source of peripheral Aβ [45] 
and the main storage site of serotonin outside the brain 
[40]. Furthermore, AD-related changes in APP metabolism 
[16], monoamine oxidase B (MaoB) enzymatic activity and 
protein expression have been detected in platelets [4, 75]. 
Despite a variety of molecular alterations, a comprehensive 
proteomic analysis of platelets from a large cohort to iden-
tify an AD-specific biomarker signature has not yet been 
performed.
In the present study, we sought to reveal reliable AD bio-
markers by two-dimensional differential gel electrophoresis 
(2D-DIGE) and aimed to develop a high-throughput, rou-
tine-applicable analytical system. The latter is fundamen-
tally important in the field of biomarker establishment as it 
still represents the bottleneck in the translation of research 
findings into clinical practice [44]. While DNA- and RNA-
based microarrays are in widespread use, protein biochips 
are thus far rarely applied. However, since multiple patho-
physiologic events of AD finally take place at the protein 
level [76], this suggests that phenotyping with a protein 
biochip might be at least as comprehensive as DNA geno-
typing or mRNA quantification.
Analysing platelet proteins from AD patients and 
matched cognitively healthy controls in independent dis-
covery and verification cohorts by 2D-DIGE, we iden-
tified five LOAD-regulated protein isoforms which we 
combined in a sum score. Thus, in this work we report a 
high-throughput device that has great potential to overcome 
shortcomings of current AD diagnosis by identification of 
an AD-specific phenotype in a single analytical step.
Materials and methods
Study design and subjects
The cognitive state of 62 clinically suspected LOAD 
patients was assessed using the neuropsychological test 
battery of CERAD (Consortium to Establish a Registry for 
Alzheimer’s Disease) on the day of blood sampling [71]. 
No patient had been medicated with AD-related therapies 
such as acetylcholinesterase inhibitors (e.g. donepezil) or 
NMDA-receptor antagonist (e.g. memantine). Moreover, 
no patients received antipsychotic drugs or antidepressants. 
To exclude other causes of cognitive impairment like stroke 
or tumours, all patients underwent structural brain scanning 
using MRI, except two patients who were assessed using 
CT because of claustrophobia or metal implants. Diagnoses 
were established using the standardized CERAD criteria 
evaluated from clinical history, brain imaging, and neu-
ropsychological tests [2]. Accordingly, clinical classifica-
tion of AD patients was defined by two or more deficits in 
cognition, progressive worsening of memory and other cog-
nitive abilities [3], and onset age between 65 and 85 years. 
Further selection criteria were severe temporal lobe atro-
phy on MRI and exclusion of other forms of dementia (i.e. 
vascular dementia, VaD). In nine patients, clinical diagno-
sis was neuropathologically confirmed post mortem [48]. 
Additionally, we included 24 amnestic mild cognitive 
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impairment (aMCI) patients characterized by neuropsycho-
logical CERAD testing [21]. Twelve idiopathic Parkinson’s 
disease (PD) and 13 VaD (four post-mortem-confirmed) 
patients were also assessed and their cognitive status indi-
cated by mini-mental state examination (MMSE).
MCI patients were selected according to the criteria of 
the consensus conference in Stockholm in 2003 [69] and 
the Diagnostic Manual for Dementia [3]. Neuropsycho-
logical criteria of aMCI were a MMSE greater than 25, not 
demented, intact activities of daily living, and an impair-
ment in at least two domains of memory with z less than 
−1.0 using diagnostic comprehensive criteria [38]. On the 
other hand, 112 age- and sex-matched control subjects, 
who displayed no signs of neurodegenerative and psychiat-
ric diseases, were interviewed, neuropsychologically exam-
ined (CERAD), and selected by three experienced psychol-
ogists prior to enrolment to exclude cognitive impairment. 
All individuals were non-smokers. Demographic data and 
clinical characteristics of the study population are detailed 
in Tables 1 and OR1 (the latter in the Electronic Supple-
mentary Material).
The study was approved by the ethics commission 
of the city of Vienna, Austria, EK-04-070-0604 and EK 
09/219/1209. Each participant and/or legal guardian was 
advised of the purpose and procedures of the study and 
written informed consent was obtained prior to initiating 
the study in accordance with the principles of the Declara-
tion of Helsinki.
Neuropathological examination of suspected AD and VaD 
patients
In nine of the 62 AD patients, clinical diagnosis was 
neuropathologically confirmed. These patients died 
10–18 months after sample collection. Neuropathological 
diagnoses were made according to established post-mortem 
consensus criteria for AD, including CERAD scores [52]. 
AD cases displayed neuropathological changes consist-
ent with Thal phase for Aβ plaques 5.6 [65], CERAD C, 
and Braak stages V/VI [10], thereby fulfilling the criteria 
for AD neuropathological changes according to the Alz-
heimer’s Association guidelines of the National Institute 
on Aging [53]. As described previously [75], neuropatho-
logical examination included haematoxylin/eosin stain-
ing, modified Bielschowsky impregnation, as well as tau, 
Aβ, and α-synuclein immunohistochemistry. VaD in four 
additional cases was diagnosed following the guidelines by 
Kalaria and colleagues [41].
Blood sampling and sample preparation for 2D-DIGE
Blood collection, platelet isolation, platelet protein extrac-
tion, total protein concentration determination, and fluo-
rescence labelling for proteome analysis by 2D-DIGE are 
described elsewhere [67] and detailed in online resource 
(OR) Information OR1–OR3.
2D-DIGE and MS analysis of gel-filtered platelets 
for biomarker identification
The platelet proteome was investigated by 2D-DIGE in two 
pH ranges (pH 4–7 and 6–9) on 25.5 × 20.5 cm gels to 
achieve an optimal protein resolution. 2D-DIGE and image 
analysis were performed as described previously [70], 
details are specified in Information OR3. Proteins were 
identified after tryptic digestion, nanoflow liquid chroma-
tography (1100 Series LC system, Agilent, Palo Alto, CA, 
USA), and MS/MS fragmentation analysis with an iontrap 
Table 1  Demographic details of AD and control study participants
Samples (AD, n = 62; Co, n = 63) were exclusively derived from non-smokers; subjects with metabolic syndrome and diabetes mellitus type 2 
were excluded from analyses. Hypertension was reported for 11 % of AD patients and 19 % of controls; 7 % of AD patients and 5 % of controls 
were treated with lipid-lowering drugs. Significances of p values (1) were calculated with the Mann–Whitney U test, significances of genotype 
distributions (2) by Pearson chi square using ad hoc continuity correction by adding 0.5 to empty cells
Co controls, MMSE mini-mental state examination, NS not significant
a
 Percentage of APOE ε4-positivity (homo- or heterozygous)
Demographic variable Discovery set Verification set All
AD (n = 22) Co (n = 25) AD (n = 40) Co (n = 38) p value
Mean age (±SD), (years) 81 (±8.2) 80 (±8.5) 82 (±6.2) 81 (±6.3) NS (1)
MMSE (SD) 5.5 (±4.2) 29 (±0.8) 14 (±7.1) 29 (±0.9) <0.001 (1)
% Female 82 86 81 81 NS (1)
% APOE ε4+/a 68 8 68 11 <0.001 (2)
% APOE ε4+/+ 27 0 14 0 <0.001 (2)
Platelet c × 103/µl (±SD) 293 (±79) 266 (±58) 220 (±71) 243 (±152) NS (1)
Education (± SD), (years) 10.4 (±3.0) 10.9 (±2.6) 11 (±3.3) 12.1 (±2.7) NS (1)
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mass spectrometer (XCT-Plus, Agilent). Details have been 
published previously [60] and are described in Information 
OR4.
APOE ε4 and GSTO1*A140 genotyping
APOE ε4 genotyping was performed according to Crook 
et al. [18], GSTO1*A140 genotyping according to Veitinger 
et al. [67].
Sample preparation of PRP for protein biochip
Platelet-rich plasma (PRP) was prepared as described in 
Information OR1 and subsequently stored at −80 °C. After 
thawing, 100 µl PRP was centrifuged (3 min, 3,000×g) to 
separate platelets from supernatant platelet-poor plasma 
(PPP). Ninety microlitres of PPP was mixed with 10 µl of 
10× RIPA buffer and incubated (25 min, 4 °C). In paral-
lel, the pelleted platelets were thoroughly resuspended in 
20 µl SDS buffer and incubated (25 min, 4 °C). Thereaf-
ter, platelet SDS lysates were pooled with 10 µl of RIPA-
PPP fraction, with addition of 70 µl 2 % BSA/PBS buffer 
to bind excess SDS, and incubated (25 min, 4 °C) before 
application onto the protein biochip. A schematic workflow 
is presented in Fig. OR1, a protein biochip work instruction 
overview in Text OR2.
Statistics
After a Kolmogorov–Smirnov test had confirmed that the 
data did not show a Gaussian distribution, we selected non-
parametric analysis. Mann–Whitney U test was used to 
estimate differences between patients and controls. Sam-
ple size determination was based on the algorithm pub-
lished in our previous study [70]. Statistical significance 
was set at p < 0.05 for all tests and corrected for multiple 
comparisons [32] of 890 protein spots of the discovery 
phase (Table OR2) and across both study phases (Table 2). 
Adjustment was made by the R package “stats”. Only those 
effects on the platelet proteome that (a) were derived from 
spots matched in more than 80 % of all 2D gel images, 
(b) showed an SA ratio (AD/controls) greater than 1.20 or 
smaller than 0.80, (c) had an unadjusted p value less than 
0.05 in the discovery phase, and (d) an adjusted p value less 
than 0.05 in the verification phase, as well as (e) across the 
whole study collective were regarded as significant. Clini-
cal accuracy of examined parameters was assessed using 
receiver operating characteristic (ROC) curve analysis. 
ROC blots were constructed and AUC, standard errors, 
95 % CI, sensitivity, and specificity calculated. Cut-off 
values for the best discrimination of positive and nega-
tive diagnoses were set by the least squares method using 
SPSS 20 (SPSS inc, Chicago, USA). Cohen’s d was used 
as a measure of effect size (ES) and calculated with the for-
mula (mean 1 − mean 2)/[(SD 1 + SD 2)/2]. To combine 
the single AD biomarkers into a score value, sum scores 
and logistic regressions were calculated using the R pack-
age “logistf” for fitting a logistic regression model apply-
ing Firth’s correction to the likelihood. Correlations were 
defined with the Pearson correlation coefficient. Signifi-
cances of genotype distributions were determined by Pear-
son chi square using ad hoc continuity correction by adding 
0.5 to empty cells.
Results
Platelet proteome analysis of AD patients
To detect reliable AD-specific biomarkers in platelets, 
we designed the 2D-DIGE investigation in two stages 
(Table 1). In the discovery phase, comparison of pro-
teomes derived from 22 AD patients and 25 controls with 
the applied spot filter criteria revealed ten significantly 
changed protein spots out of 890 spots matched in more 
than 80 % of all gels (Table 2). Note that the two inflamma-
tion-indicating acute phase proteins C-reactive protein and 
haptoglobin analysed in plasma of 18 AD patients and 21 
controls (discovery cohorts) were not significantly differ-
ent, indicating no seriously compromised health status due 
to the disease or biasing comorbidities. To avoid inclusion 
of false positives (overfitting), verification of the ten iden-
tified candidates was sought using 40 newly recruited AD 
patients and 38 controls. Consequently, the filter criteria 
in this study phase were set to adjusted p values less than 
0.05 for ten comparisons. At this stage, the top four ranked 
protein spots were confirmed by unadjusted and adjusted 
p values [32]. Likewise, these AD-related isoforms had an 
adjusted p value less than 0.05 if corrected for 890 com-
parisons when calculated across the whole study cohort 
(Table 2). Six biomarker candidates from the discovery 
phase could not be verified and were excluded from further 
analyses. The most significant (p = 3.42 × 10−7) expres-
sional upregulation in AD patients was that of MaoB spot 
B645 (Figs. 1, OR2b). ApoE spot A1942 demonstrated a 
decreased expression and was attributed to the ε3 isoform 
(Figs. 1, OR2a) (p = 0.0009). Accordingly, this spot exhib-
ited lower SA in ε4-positive patients. The increased ApoE 
spot A1929 was assigned to the ε4 isoform (p = 0.001). 
The fourth strongest confirmed AD-regulated spot A1855 
was identified as tropomyosin 1 (Tm1) (p = 0.008). Adja-
cent spots A1827, A1896, and A1941 (Fig. 1) were also 
recognized as Tm1 (Fig. OR2c). Glutathione S-transferase 
omega 1 (GSTO1) spots A2000 and 2006 (Fig. 1) exhib-
ited reduced expressions; however, this was not confirmed 
in the verification phase (Table 2). Nonetheless, there was a 
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strong association with the APOE genotype in AD patients 
which we assessed in more detail.
Non-APOE ε4 AD patients overrepresent GSTO1 isoform 
A140
Since studies have reported distinct biochemical profiles 
of AD sufferers with respect to their APOE genotype [61], 
we genotyped all subjects and subdivided them into APOE 
ε4 carriers and non-carriers. As expected, the AD group 
included significantly more APOE ε4 carriers (68 %) than 
the control group (11 %). All confirmed AD-related protein 
spots were also significantly changed in these subgroups 
(Table OR2). The two GSTO1 spots A1998 and A2000, 
previously identified by our laboratory as isoforms of SNP 
rs4925 [67], displayed significant modulation in APOE ε4 
non-carriers (Table OR2): spot A1998 was upregulated to 
1.61 (p = 0.020) in ε4-negative patients, isoform A2000 
was significantly decreased to 0.41 (p = 0.037). The lower 
abundant isoform A2006 was not significantly downregu-
lated to 0.43 (p = 0.095). Similarly, all three autopsy-
confirmed (a.c.) APOE ε4-negative patients expressed 
exclusively GSTO1*A140. Furthermore, neuropathology 
assigned three APOE ε4-negative probable AD patients, all 
of which were heterozygous for SNP rs4925, as exhibiting 
vascular dementia. Additionally, the top four proteins dis-
played highly significant expression changes also in the a.c. 
AD subgroup (Table OR2). Consequently, all these markers 
were included in the AD panel together with the GSTO1 
isoforms.
Validation of GSTO1*A140D distribution by PCR analysis 
of SNP rs4925
To underscore the above finding, we genotyped all par-
ticipants and confirmed the 2D-DIGE data (Fig. OR3) 
that exclusively two GSTO1*A140 alleles were present in 
non-APOE ε4 AD patients (n = 20) as compared to 32 % 
in APOE ε4-positive patients and 38 % in controls (30 % in 
non-APOE ε4 controls).
Models of AD biomarker combinations
In order to establish the most powerful biomarker algo-
rithm to identify AD samples, we reviewed different com-
binations of the significantly changed proteins/isoforms 
(Table 3). Combinations for optimal distinction between 
diseased and healthy were calculated separately for the 
discovery and verification sets, and for the whole collec-
tive using primary sum scores. For these scores, we inte-
grated the APOE ε4 allele count instead of SA since there 
was considerable background noise in the area of the 
2D-DIGE ApoE4 spot A1929 (Fig. 1) in ε4-negative indi-
viduals. The sum score of the top-ranked protein MaoB and 
the APOE ε4 allele count (model 2) increased the AUC of 
MaoB alone (model 1) from 0.823 (ES = 1.27) to 0.896 
(ES = 1.80). Inclusion of Tm1 A1855 (model 3) moder-
ately improved this AUC to 0.904 (ES = 1.93). Addition of 
GSTO1*A140 SA (model 4), overrepresented in APOE ε4 
non-carriers, lowered the AUC to 0.901 (ES = 1.81). Most 
importantly, introducing the APOE ε4 allele into a decision 
tree (Table 3, model 5) yielded the highest AUC of 0.969 
(95 % CI = 0.944–0.994, ES = 2.50). With this model, we 
could differentiate patients from controls with 94 % sensi-
tivity and 89 % specificity. Consequently, this study utilized 
two algorithms dependent on the absence (5a, addition of 
GSTO1*A140) or presence of at least one APOE ε4 allele 
(5b, addition of GSTO1*D140). This model demonstrated 
a robust performance in the discovery (AUC = 0.952) and 
verification (AUC = 0.980) phase with a high separation 
power independent from gender. Similarly, the combination 
of these biomarkers by logistic regression yielded an AUC 
of 0.966 (95 % CI = 0.940–0.991, cut-off = 0.510: sensi-
tivity = 92 %, specificity = 86 %). 
Fig. 1  Representative 
2D-DIGE array with AD-
regulated proteins highlighted: 
45 µg total CyDye-labelled 
platelet protein extracts were 
separated (15 µg each from an 
AD patient, a matched control, 
and the IS) in the pH ranges 4–7 
(a) and 6–9 (b). Spots differen-
tially expressed in AD patients 
(n = 62) and controls (n = 63) 
are marked (spot ID and 
UniProt number after identifica-
tion by MS) with ERK2 (spot 
B1115) as loading control (LC) 
on the protein biochip
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Accuracy of model 5 algorithm for identification of AD 
patient
To investigate whether AD patients can be discriminated 
from other neurodegenerative disease patients, we ana-
lysed 24 aMCI, 12 PD, and 13 VaD patients (Table OR1) 
by 2D-DIGE. Using the model 5 algorithm, AD patients 
could be separated from PD with high (AUC = 0.912) and 
from VaD with still moderate (AUC = 0.738) precision. 
Remarkably, differentiation of post-mortem-confirmed VaD 
cases (n = 4) from AD subjects was even more pronounced 
(AUC = 0.915). An AUC of 0.798 could be achieved for 
discrimination of aMCI patients and controls (Table OR3).
Development of a novel protein biochip for AD detection
To enable high-throughput analysis of the identified specific 
AD phenotype, we engineered a protein biochip combining 
protein quantification and proteomic genotyping (Fig. 2). 
This included establishment of a new sample preparation 
method (Fig. OR1) for simultaneous quantification of plas-
matic, cytosolic, and membrane proteins, implementation 
Table 3  Performance of different biomarker combinations of discovery, verification, and pooled sample sets
Spot SA (2D-DIGE) of the significant platelet proteins MaoB and Tm1 (A1855) were combined with the APOE ε4 allele count by summation. 
In the split algorithms (a and b), GSTO1*A140 SA was added to APOE ε4-negative samples, GSTO*D140 SA to APOE ε4-positive samples. 
ROC curves were calculated for the discovery (n = 47), verification (n = 78), and pooled (n = 125) sample sets. Biomarker combinations 
marked in bold were the best for 2D-DIGE (model 5) or the protein biochip (model 6) with highest AUCs. Model 6 simulates the design of the 
developed protein biochip, whereby instead of GSTO1 SA the allele counts (adjusted with a coefficient according to their 2D-DIGE abundance) 
were taken
Biomarker algorithm Statistics
Model Algorithm Standardised abundances of 2D-DIGE Allele count Discovery 
(n = 47)
Verification 
(n = 78)
All (n = 125)
MaoB
B645
Tm1
A1855
GSTO1*A140
A1998
GSTO1*D140
A2000
APOE ε4 AUC AUC AUC 95 % CI ES
0 0 − − − − + 0.797 0.782 0.787 0.704–0.869 1.40
1 1 + − − − − 0.838 0.821 0.823 0.748–0.898 1.27
2 2 + − − − + 0.865 0.912 0.896 0.842–0.955 1.80
3 3 + + − − + 0.890 0.910 0.904 0.851–0.956 1.93
4 4 + + + − + 0.893 0.916 0.901 0.849–0.954 1.81
5 5a + + + − − 0.952 0.980 0.969 0.944–0.994 2.50
5b + + − + +
6 6a + + + (*0.6) − − 0.944 0.949 0.947 0.884–0.998 2.36
6b + + − + (*0.9) +
Fig. 2  Schematic representation of the new AD multiplex protein 
biochip. a Antibodies directed against the proteins of interest were 
spotted on the biochip, incubated with samples (or calibrators) and 
target analyte concentrations quantified by measuring chemilumines-
cence signals of bound HRP-labelled secondary antibodies. b Quan-
tification of GSTO1*A140 (orange circles) and ApoE4 (red circles) 
with the protein biochip. Together with the image in a, all four pos-
sible genotypes (APOE ε4−/GSTO1*A140, APOE ε4+/GSTO1*A140, 
APOE ε4−/GSTO1*D140, APOE ε4+/GSTO1*D140) are shown. c 
Quantitative protein expression differences of Tm1 (purple squares) 
and MaoB (blue squares)
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of an additional assay for a stably expressed loading con-
trol (LC) in order to optimize sample normalization, and 
development of highly specific peptide antibodies to dis-
criminate protein isoforms. We raised monoclonal antibod-
ies against AD-related proteins in-house and confirmed 
high specificity and functionality on 2D-WB membranes 
(Figs. OR2a, OR2b; Text OR1).
Low biological variation proteins were systematically 
evaluated as potential LCs in psychiatrically diseased and 
healthy subjects [6] to compensate for variation in plate-
let numbers which was observed to be 36 % in 102 PRP 
samples (363 ± 131 × 103 platelets/µl). LCs circumvent 
inconvenient platelet counting and total protein determina-
tion which is not possible because of high plasma protein 
content in PRP lysates (Fig. OR1). ERK2 was selected as 
LC for one-step normalization on this biochip because of 
its AD-independent expression (Table OR2; Fig. OR4), its 
smooth technical performance on the biochip, and its pre-
vious use as LC on WB for Aβ-activated microglia [62]. 
Biochip feasibility studies of ERK2-normalization were 
performed by repeated analysis of different dilutions of 
highly concentrated endogenous PRP samples (Fig. OR5). 
Linear regression analysis of ERK2 concentration against 
the respective platelet number demonstrated a high correla-
tion coefficient (r = 0.99).
The advantage but also challenge of a multiplex array is 
the combination of several assays on a single platform. A 
detailed description of the protein biochip technology has 
been published previously [23], the assembly of the novel 
AD biochip is outlined in Fig. 2a. One pair of antibodies 
was required for each target protein, comparable to a sand-
wich ELISA. Calibration curves with affinity purified pro-
teins for each individual assay are presented in Fig. OR6.
An easy sample preparation protocol applicable for rou-
tine analysis was developed and is detailed in Fig. OR1 and 
Text OR2. Notably, a simple SDS buffer was superior to 
several other commonly used detergents, compatible with 
all assays, and most efficient in extracting the membrane 
protein MaoB. To quantify proteins released by platelets 
during freezing/thawing and to facilitate protein-based 
APOE genotyping (higher abundance in plasma), a plas-
matic fraction was included. Separate treatment of platelets 
and PPP with subsequent fusion enables parallel analysis 
of cellular, membrane, and plasmatic proteins and permits 
introduction of a dilution factor for much higher abundant 
plasma proteins.
All available 102 samples previously analysed by 
2D-DIGE were measured with the protein biochip: 21 
pairs of the discovery set and 30 pairs of the verifica-
tion set. Using the protein biochip for determination of 
GSTO1*A140 and APOE ε4 allele counts (Fig. 2a, b), 98 % 
of all samples (100 out of 102) were correctly genotyped 
for GSTO1 SNP rs4925 and 100 % correct genotyping was 
achieved for APOE ε4 by normalization with either ERK2 
or panApoE concentrations. APOE ε4 stratification con-
firmed the high prevalence of GSTO1*A140 as all 16 APOE 
ε4-negative AD patients exhibited the GSTO1*A140A gen-
otype (vs. 25 % of APOE ε4-negative controls). Moreover, 
biochip analysis replicated the higher expression of both 
quantitative markers Tm1 and MaoB (Fig. 2c) in patients 
as compared to controls. The 18 % increase of Tm1 was 
already significant without normalization (p = 0.003), the 
13 % elevated MaoB level was not (p = 0.121). After cor-
rection with ERK2, both p values significantly improved 
(pTm1 = 0.001; pMaoB = 0.006), as well as the MaoB upreg-
ulation to 17 %.
To establish a biochip sum score (Table 3, model 6), we 
also divided ERK2-normalized MaoB and Tm1 concentra-
tions by their respective average concentrations in order to 
obtain relative values like in 2D-DIGE before addition to 
the allele counts. Since the array was designed to genotype 
samples for GSTO1*A140 and APOE ε4 rather than abso-
lutely quantifying the protein abundances, the respective 
allele numbers were used in model 6. According to their 
2D-DIGE SA, weighting factors of 0.6 and 0.9 for isoforms 
A140 and D140 were introduced. The ES of 2.36 was com-
parably strong as that of 2D-DIGE model 5 and the AUC 
of 0.947 (95 % CI = 0.884–0.998) was just slightly lower.
The separation of patients and controls, as well as the 
correlation of the protein biochip with 2D-DIGE is pre-
sented in Fig. 3a. However, since a sum score is not practi-
cal for routine biochip application, we additionally calcu-
lated a logistic regression model which yielded an AUC of 
0.969 (95 % CI = 0.941–0.996; sensitivity = 94 %, speci-
ficity = 90 %, Fig. 3b). In summary, we established a novel 
high-throughput platform that achieved AD diagnosis with 
an accuracy of 92 %.
Discussion
Systematic characterization of the platelet proteome by 
2D-DIGE identified a reliable AD blood biomarker signa-
ture which we translated into a protein biochip array with 
great feasibility for routine diagnosis. In this study, we 
revealed GSTO1 as a novel AD biomarker since the A140 
isoform was significantly overrepresented in APOE ε4-
negative AD patients. Accordingly, the variant of SNP 
rs4925, D140 [5, 12, 47, 55], was underrepresented in this 
AD subgroup. Further, we identified significant protein 
expression changes apparently not linked to genetic muta-
tions: upregulated Tm1 isoforms represent novel periph-
eral diagnostic targets. Previous studies have demonstrated 
that tropomyosin is an integral part of neurofibrillary tan-
gles [26] and increased expression has been detected in 
the olfactory bulb of aged mice [57]. In humans, olfactory 
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impairment is associated with normal aging and several 
age-associated neurodegenerative disorders, including AD 
and PD [58]. Elevated levels of Tm1 have been quantified 
in periventricular white matter [13] and the glycosylated 
hippocampal proteome [20]. Higher concentrations of oxi-
datively modified tropomyosin isoforms have been found 
in the choroid plexus of AD patients [56]. Oxidative modi-
fication of Tm by reactive oxygen species (ROS) produced 
by monoamine oxidase has been linked to myofibre dam-
age in muscular dystrophy [50]. Mechanistically, formation 
of disulphide cross-bridges reduces protein solubility and 
may enforce the generation of neurofibrillary tangles in AD. 
In parallel, studies have chronicled increased activities and 
protein concentrations of the dopamine-degrading enzyme 
MaoB in AD; the latter could repeatedly be confirmed in the 
present study (Table 2). The described generation of ROS 
in turn might boost the amyloidogenic pathway e.g. via 
increasing the activity of BACE1 in AD cases [9]. In con-
trast to ApoE4 and GSTO1*A140, detailed examination 
failed to established any correlation of MaoB expression 
with its most frequently described SNP rs1799836 [39]. 
Instead, MaoB concentrations correlated with smoking [42], 
ageing [75], and inversely with plasma vitamin B12 concen-
tration [74]. Therefore, MaoB expression might indicate a 
functional molecular link of lifestyle and AD pathogenesis 
potentially via epigenetic regulation through the one-carbon 
metabolism [74]. A mechanistic hypothesis on the elevated 
expression of MaoB [42], Tm1 [72], and BACE1 [25] is a 
deregulated one-carbon metabolism which leads to reduced 
promoter methylation and, consequently, to increased pro-
tein expression. Regarding the tau pathology, a reduced 
methylation of protein phosphatase 2A with concomitant 
tau hyperphosphorylation has been described [63].
The highly significantly altered expression of ApoE4 in 
the AD platelet proteome confirmed this SNP as the most 
powerful risk factor for LOAD besides ageing. However, 
the relatively low AUC of 0.787 (Table 3, model 0) for the 
APOE ε4 allele count reflects limited diagnostic sensitivity/
specificity [7]. In accordance with previous studies, we found 
that 10–16 % of cognitively healthy elderly carry at least one 
ε4 copy [59], while it is present in about 60 % of autopsy-
confirmed AD patients [43]. A similar APOE ε4 distribution 
has also been published in the ADNI study [15]. However, 
this indicates that roughly half of all AD patients are APOE 
ε4-negative and alternative biomarkers specific for this sub-
group are required. APOE ε4 stratification revealed signifi-
cant changes in the distribution of the two GSTO1 protein 
spots A1998 and A2000 in APOE ε4-positive and APOE 
ε4-negative AD patients (Fig. OR3; Table OR2). Initially, 
GSTO1*D140 was reported to be associated with a later 
age-at-onset [46]; however, follow-up studies could not con-
firm this finding [5, 12, 55]. Notably, none of these studies 
presented data about the SNP rs4925 distribution in APOE 
ε4-negative AD samples. GSTO1 has diverse functions, 
including mitigation of oxidative stress, and may underlie 
the pathophysiology of several neurodegenerative diseases. 
Recently, it has been shown that GSTO1*D140 has a higher 
glutathionylation activity than GSTO1*A140, thereby poten-
tially preventing oxidative damage of proteins [51]. A protec-
tive effect of the D140 allele has been reported for PD [5, 47].
Here, we found platelet MaoB to be the most powerful 
biomarker in the differentiation of healthy and diseased 
(ES = 1.30), corroborating previously published data [74]. 
MaoB had a higher ES than abnormally processed platelet 
APP in moderate AD patients (ES = 1.10) [73]. The diag-
nostic performance of Tm1 A1855 (ES = 0.76) was com-
parable with decreased BACE1 levels (ES = 0.85) [19], 
decreased platelet phospho-GSK3B levels (ES = 0.68) [24], 
or plasma Aβ42/Aβ40 ratio (ES = 0.80) [30]. Although 
all of these AD biomarkers differed significantly between 
Fig. 3  Statistical analysis of 51 AD and 51 control samples with 
2D-DIGE and the protein biochip. a Scatter plot of sum scores (arbi-
trary units, n = 102) derived by addition of APOE ε4 and GSTO1 
allele counts to MaoB and Tm1 concentrations (models 5 and 6 of 
Table 3). Protein biochip sum scores are plotted on the x axis, those 
of 2D-DIGE on the y axis. Red squares AD samples; green cir-
cles control samples. b ROC curve of the logistic regression calcu-
lated for the 102 clinical samples analysed with the protein biochip 
(AUC = 0.969)
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AD and controls, none of them reached the sensitivity and 
specificity claimed [35, 66]. Several studies focusing on 
combinations of biomarkers revealed higher discriminat-
ing power for algorithms than for single candidates [17, 
34, 77]. Likewise, unifying the well-known AD biomark-
ers MaoB and APOE ε4 with the novel candidates Tm1 and 
GSTO1 (Table 3) generated a highly disease-specific test 
(AUC = 0.969). This diagnostic accuracy of 92 % better 
conforms with clinical requirements for dementia diagno-
sis [66] and has a similarly good diagnostic performance as 
established CSF biomarkers [64]. The scores in Table 3 fur-
thermore indicate similar diagnostic accuracy independent 
of the stage of AD patients: AUC values were comparably 
high for late stage (mean MMSE discovery set = 5.5 ± 4.2) 
and mild/moderate stage (mean MMSE verification 
set = 14 ± 7.1) AD patients as evident in e.g. model 5 with 
AUC values of 0.952 (discovery phase) and 0.980 (verifi-
cation phase). Additionally, first comparisons with subjects 
suffering from PD, VaD, or aMCI indicate that this algo-
rithm is fairly specific for AD and may already indicate 
prodromal disease stages. Consequently, we engineered and 
validated a multiplex system for high-throughput analysis. 
Several technical issues had to be considered: an optimal 
lysis procedure is defined by the biochemistry of the pro-
teins of interest and the analytical platform (Fig. OR1). 
While mild buffers are appropriate for solubilisation of 
cytosolic proteins and determination of enzymatic activity, 
stronger detergents are required to extract membrane pro-
teins. The use of SDS for cell lysis is well established and 
has already been applied to blood platelets [33]. However, 
reports about a sole SDS-based lysis of pelleted platelets are 
sparse as SDS treatment is almost exclusively used for sub-
sequent matrix-based protein separation techniques such as 
SDS-PAGE. Detection of soluble SDS-extracted proteins by 
ELISA is an exception [28]. Nevertheless, ionic SDS was 
the most effective detergent and rendered compatible with 
all assays on the protein biochip. Integration of an LC has 
ensured that this is the first device to offer multiplexed quan-
tification of cellular and plasmatic proteins in a single ana-
lytical step. These technical innovations are not limited to 
AD diagnosis but have a wide field of further applications.
Translation of our 2D-DIGE data to the new protein bio-
chip yielded analogous results: analysis of a well-defined AD 
collective versus healthy controls generated high accuracy of 
92 % (Fig. 3). With this carefully validated diagnostic kit, 
sample sizes including that of MCI and other dementia sub-
types, to determine the broader efficacy of this platelet array, 
can be increased in the future. Of particular interest is fur-
ther assessment of the pathologic significance of this platelet 
biomarker panel in patients with incipient AD and follow-up 
of aMCI patients. In summary, we demonstrate the utility of 
measuring multiple analytes from a PRP preparation in a sin-
gle step to aid the diagnosis of LOAD.
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